Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions

Merck KGaA is posting some of their mid-stage data from a trial of their BTK inhibitor evobrutinib for multiple sclerosis. But despite a bold boast that the drug represents just how innovative their in-house R&D group is, the data are distinctly mixed.